Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Gene Therapy

Danaher will acquire Aldevron for $9.6 billion

by Rick Mullin
June 26, 2021 | A version of this story appeared in Volume 99, Issue 24

 

Danaher, a supplier of health-care and process industry products, has agreed to acquire Aldevron, a supplier of plasmid DNA, messenger RNA, and recombinant proteins used in the manufacture of vaccines and cell and gene therapies, for $9.6 billion. Headquartered in Fargo, North Dakota, Aldevron employs about 600 people. The company plans to more than triple capacity this year by adding an 18,000 m2 facility to its 6,500 m2 operation in Fargo. The seller, the private equity firm EQT, bought a majority interest in Aldevron in 2019.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.